New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 19, 2012
15:27 EDTA, XUE, PWRD, JACK, CHRM, CRMT, URBN, NUAN, DY, BRCD, AMCN, QIHU, KKD, CO, BOBECompanies reporting After the Market Close on Monday, November 19
Notable companies reporting after the closing bell on Monday include Agilent Technologies (A), Airmedia Group (AMCN), America's CAR-MART (CRMT), Bob Evans Farms (BOBE), Brocade Communications Systems (BRCD), Charm Communications (CHRM), China Cord Blood Corp (CO), Dycom Industries (DY), Jack In The Box (JACK), Krispy Kreme Doughnuts (KKD), Nuance Communications (NUAN), Perfect World (PWRD), Qihoo 360 Technology (QIHU), Urban Outfitters (URBN), and Xueda Education Group (XUE).
News For A;AMCN;CRMT;BOBE;BRCD;CHRM;CO;DY;JACK;KKD;NUAN;PWRD;QIHU;URBN;XUE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
May 15, 2015
10:01 EDTDYOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:51 EDTXUEXueda Education forms special committee to evaluate previously disclosed bid
Xueda Education Group announced last night that its board has formed a committee of independent directors to evaluate the preliminary non-binding proposal letter dated April 20 from Insight Investment Co., a Chinese company listed on the Shenzhen Stock Exchange, to acquire all of the company's outstanding shares. Each of the co-founders of the company currently intend to form a consortium with Insight Investment in connection with the proposal. The founders currently beneficially own, in the aggregate, shares of the company representing approximately 58.8% of the issued and outstanding shares of the company, Xueda noted.
08:08 EDTADarwin Professional presents positive clinical data for ALD403
Alder BioPharmaceuticals announced that six-month follow-up data from its Phase 2 proof-of-concept clinical trial of ALD403, its anti-calcitonin gene-related peptide, or CGRP, antibody for the prevention of frequent episodic migraine, were presented in an oral presentation at the 17th Congress of the International Headache Society in Valencia, Spain. Key Points from Oral Session: Migraine Pathophysiology and CGRP as a Therapeutic Target: A single intravenous dose of ALD403 1000mg demonstrated prolonged efficacy over six months for the preventive treatment of migraine. Over three months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 61% vs 33%; 33% vs 9%; and 16% vs 0%, respectively. Over six months, the proportion of patients with a 50%, 75%, and 100% reduction in migraine days for ALD403 and placebo was 53% vs 28%; 26% vs 7%; and 11% vs 0%, respectively. ALD403 was well tolerated and there were no differences from placebo in terms of adverse events or laboratory safety data. The migraine prevention proof-of-concept trial was conducted in 163 patients with frequent episodic migraine who had on average nine headache days per month. Patients were given a single intravenous dose of 1000mg of ALD403 or placebo. The primary endpoint was the mean change in migraine headache days from baseline to weeks 5-8, and patients were followed for 24 weeks for additional safety and efficacy analyses.
06:16 EDTDYDycom downgraded to Underperform from Market Perform at Raymond James
Subscribe for More Information
May 14, 2015
11:56 EDTJACKJack in the Box says expects to be active in share repurchases in 2H
Says will be "regular" and "opportunistic" in repurchases.
11:51 EDTJACKJack in the Box raises dividend by 50% to 30c per share
Subscribe for More Information
11:45 EDTJACKJack in the Box says 'committed' to returning cash to shareholders
Says Q2 sales increased in all major markets. Says weather was "more of a factor" in Q2 this year vs.last year. Says during Q2, there were three weeks negatively impacted by weather for Qdoba. Says "pleased" with how both brands are performing. Says "committed" to returning cash to shareholders. Now sees FY commodity costs up approximately 2%. Says FY15 operating EPS guidance now includes expected 6c charge related to removal of existing beverage equipment in Q3 and Q4. Comments made on the Q2 earnings conference call. Jack in the Box is down 4.23% to $87.90 in late-morning trading.
10:09 EDTJACKIncreasing equity options volume on open
Increasing equity options volume on open: ONTY CBRL PBYI GWW AXLL IEV KSS EXPR UEC JACK
10:00 EDTURBNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:11 EDTJACKOptions expected to be active
Subscribe for More Information
06:40 EDTURBNUrban Outfitters upgraded to Outperform from Market Perform at Telsey Advisory
Subscribe for More Information
May 13, 2015
16:08 EDTJACKJack in the Box sees FY15 operating EPS $2.90-$3.00, consensus $2.96
Subscribe for More Information
16:07 EDTJACKJack in the Box sees FY15 Jack in the Box company-owned SSS up 4.5%-5.5%
Subscribe for More Information
16:05 EDTJACKJack in the Box sees Q3 Jack in the Box brand company SSS up 4%-6%
Subscribe for More Information
16:04 EDTJACKJack in the Box reports Q2 operating EPS 69c, consensus 67c
Reports Q2 revenue $358.1M, consensus $356.14M. Jack in the Box system same-store sales increased 8.9% for the quarter and company same-store sales increased 7.4%. Qdoba same-store sales increased 8.3% system-wide and 7.0% for company restaurants in Q2.
15:04 EDTJACKNotable companies reporting after market close
Subscribe for More Information
09:32 EDTURBNUrban Outfitters' Q1 revenues tracking above consensus, says ITG Research
Subscribe for More Information
08:08 EDTAAgilent volatility elevated into Q1 and sales outlook
Subscribe for More Information
May 12, 2015
13:54 EDTURBNUrban Outfitters volatility elevated into Q1 and outlook
Subscribe for More Information
May 11, 2015
12:11 EDTNUANNuance downgraded to Hold from Buy at Standpoint Research
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use